Supply setipiprant 99% CAS 866460-33-5 for Anti-Hair Loss

FOB Reference Price:Get Latest Price
  • 1 - 99 Grams
    $10.00
  • >=100 Grams
    $6.50
Lead Time:
Quantity(Grams) 1 - 1000 >1000
Est. Time(days) 7 Negotiable
Customization:
Customized logo (Min. Order: 100 Grams)
Customized packaging (Min. Order: 100 Grams)

More

Graphic customization (Min. Order: 100 Grams) Less
Samples:
$10.00 /Gram | 1 Gram (Min. Order) | Buy Samples
Report Suspicious Activity
Overview
Quick Details
Place of Origin:
Hubei, China
Brand Name:
HHD
Type:
Pharmaceutical Intermediates, anti-hair loss products
CAS No.:
866460-33-5
Purity:
99% min
Application:
anti-hair loss,hair growth
Other Names:
Setipirant
MF:
C24H19FN2O3, C24H19FN2O3
EINECS No.:
NA
Appearance:
white powder, White Powder
Product Name:
99% setipirant powder
Specification:
99% min
Main function:
anti-hair loss
CAS:
866460-33-5
Shelf life:
2 Years
Packaging & Delivery
Lead Time :
Quantity(Grams) 1 - 1000 >1000
Est. Time(days) 7 To be negotiated
Product Description

Product name: Setipiprant
CAS NO: 866460-33-5
Purity:99%
MF :C24H19FN2O3
Grade: Medicine Grade


Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action. While it is too early to tell whether setipiprant will be an effective treatment for this condition, the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly.

A phase 2A study is underway to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo and the active comparator, finasteride, in 18 to 41 years old males with androgenetic alopecia.

Test Report
Application

Setipiprant is the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of Setipiprant have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery. 

Our Company

Wuhan HengHeDa Pharm Co., Ltd is a hi-tech enterprise locates in Wuhan Private Science and Technology Park, specializing in custom synthesis, manufacture and import & export of fine chemicals, APIs and pharmaceutical intermediates. HengHeDa Pharm has complete administration management and a good work team, which makes it growing fast in chemicals and pharmaceutical industry.

Our Factory & Lab
Related Products
Product Name
CAS
Standard
Grade
Dutasteride
164656-23-9
USP/BP/CP
Tech-grade,Pharm-grade
Finasteride
98319-26-7
USP/BP/CP
Tech-grade,Pharm-grade
Minoxidil
38304-91-5
USP/BP/CP
Tech-grade,Pharm-grade
Fevipiprant
872365-14-5
USP/BP/CP
Tech-grade,Pharm-grade
CB-03-01
19608-29-8
USP/BP/CP
Tech-grade,Pharm-grade
OC000459
851723-84-7
USP/BP/CP
Tech-grade,Pharm-grade
RU58841
154992-24-2
USP/BP/CP
Tech-grade,Pharm-grade
WAY 316606
915759-45-4
USP/BP/CP
Tech-grade,Pharm-grade
Packing & Delivery

Packaging Details

1kg with double plastic container inside/Aluminum foil bag

25kg with double plastic container inside/Fiber drum outside.

Or as your request.